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Bicyclol, an antihepatitis drug developed by Chinese scientists, has been shown to prevent the malignant transformation
induced by 3-methylcholanthrene and 12-O-tetradecanoylphorbol-13-acetate in WB-F344 rat liver epithelial cells. This study
provides further evidence on its role as a chemopreventive agent in experimental mice with diethylnitrosamine- (DEN-)
initiated and phenobarbital- (PB-) promoted liver carcinoma. Liver tissue and serum were collected. In the two-stage model
of hepatocarcinogenesis in mice, oral administration of bicyclol (100, 200mg/kg) before DEN injection showed signiﬁcant
reduction in the incidence of hepatocellular foci, nodules, or carcinoma. Histopathological examination revealed that there was
no hepatocellular carcinoma (HCC) and hepatoma formation in the mice pretreated with bicyclol (200mg/kg) at week 20,
while the mice treated with DEN/PB developed 33.3% HCC and 55.6% hepatoma. Furthermore, the serum levels of alanine
aminotransferase (ALT), alkaline phosphatase (ALP), and α-fetal protein (AFP) in serum signiﬁcantly increased in the DEN/PB
modelgroupincomparisonwiththecontrolgroup.Pretreatmentwithbicyclolshowedamarkedreductionintheabovecondition.
Bicyclol also decreased the expression of AFP and proliferating cell nuclear antigen level in the liver tissue and attenuated the
decrease in body weight. In this study, we also found that 10 weeks after stopping the administration of PB and drugs, the control
and bicyclol-treated (200mg/kg) animals showed no HCC and hepatoma formation at the time of termination whereas DEN/PB-
induced mice developed 100% hepatoma and 50% HCC. These results further indicate that bicyclol has the chemopreventive
potential for liver carcinogenesis induced by carcinogens.
1.Introduction
Hepatocellular carcinoma (HCC) comprises 90% of the liver
tumorsoccurringworldwideinhumans,withmorethanhalf
a million new cases reported every year. Diagnosis of this
cancer,oncerestrictedmostlytoAsia,isnowrisinginEurope
as well as in North America [1]. Environmental factors,
such as hepatitis virus infections and chemical carcinogen
exposure, are causally implicated in HCC occurrence. About
80% of human HCC cases are attributable to infection [2].
Chronic hepatitis B virus (HBV) carriers are 100–400 times
more likely to develop HCC than noncarriers [3]. Hepatitis
C virus (HCV) is the second most common cause of HCC
after HBV [4]. Currently, HCC represents more than 4% of
allcancercasesintheworldandcausesatleast315,000deaths
every year [5]. Although early HCC can be cured by surgical
resection, many HCC cases are asymptomatic; thus, most
HCC patients are not diagnosed in time.
An eﬀective approach to cancer control is chemopre-
vention, which is expected to interfere with the initiation,
promotion, or progression of carcinogenesis. Generally,
long-term therapy is required for both chronic HBV and
HCV. An antihepatitis drug can be considered to be of great
clinical value if it inhibits or suppresses the development of
hepatocarcinogenesis besides its improvement of abnormal
liver function and inhibition of hepatitis virus replication.2 Journal of Biomedicine and Biotechnology
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Figure 1: The chemical structure of bicyclol.
Bicyclol (4,4 -dimethoxy-2,3,2 ,3 -dimethylene-dioxy-6-
hydroxymethyl-6 -carbonyl-biphenyl) is a novel antihepati-
tis drug developed by Chinese scientists (Figure 1)[ 6]. Clin-
ical trials found that bicyclol is eﬀective in improving abnor-
malliverfunctionandininhibitingthereplicationofHBVin
chronic hepatitis B patients [7]. Pharmacologically, bicyclol
exhibits a protective action against liver injury induced by
hepatotoxins in mice and rats, an antiﬁbrotic eﬀect on CCl4-
induced liver ﬁbrosis in rats and mice, and an antihepatitis
virus action in duck viral hepatitis and the 2.2.15 cell line
[6, 8, 9]. Furthermore, bicyclol induced diﬀerentiation of
human hepatocarcinoma cells (HepG2 and Bel-7402 cells)
and reduced AFB1 hepatotoxicity in rats by increasing the
detoxifying metabolism of AFB1 in rat liver [10]. In the latest
study, bicyclol showed a signiﬁcant inhibitory eﬀect on the
malignant transformation of WB-F344 rat liver epithelial
cells induced by 3-methylcholanthrene (3MC) and 12-O-
tetradecanoylphorbol-13-acetate (TPA) [10]. These results
implicate the possibility that bicyclol has a chemopreventive
eﬀect on liver carcinogenesis.
The present study aimed to further examine the eﬀect
of bicyclol on hepatocarcinogenesis induced by the chemical
carcinogens diethylnitrosamine (DEN) as the carcinogenesis
initiator and phenobarbital (PB) as the carcinogenesis pro-
moter in mice.
2.MaterialsandMethods
2.1. Chemicals and Drugs. Bicyclol, a white crystalline pow-
der with 99% purity, was kindly provided by the Beijing
Union Pharmaceutical Plant and was suspended in 0.5%
sodium carboxymethylcellulose (Na CMC) for in vivo use.
DEN, PB, dithiothreitol (DTT), phenylmethanesulfonyl ﬂu-
oride (PMSF), aprotinin, leupeptin, N,N -methylene-bis-
acrylamide, and acrylamide were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). The kits for ala-
nine aminotransferase (ALT), aspartate aminotransferase
(AST), and alkaline phosphatase (ALP) determinations were
purchased from Beihuakangtai Chemical Reagent Co., Ltd
(Beijing, China). The ELISA kit for α-fetal protein (AFP)
determinations was oﬀered by Shanghai Shenxiong Biotech
Company (Shanghai, China). All the other chemicals used
were of analytical grade and were supplied by the Beijing
Chemical Agents Company (Beijing, China).
2.2. Animals. Male ICR mice weighing 25–27g (5 weeks old)
were purchased from the Beijing Weitonglihua Experimental
Animal Co., Ltd (Beijing, China). All mice were bred and
maintained under constant conditions at a temperature of
24◦C ± 1◦C and humidity of 55% ± 5% with 12h light and
12h dark cycles. Water and feed were accessible to the mice
ad libitum. Animal care and all experimental procedures
were conducted in accordance with the health criteria for
care of laboratory animals enacted by the Beijing municipal
government.
2.3. Experimental Protocol. The experimental mice were
randomly divided into 4 groups, and each group contained
15 animals housed at 5 per cage. Liver cancers were induced
in all the groups with a single i.p. injection of DEN at a dose
of 100mg/kg body weight in normal saline, except in the
control group. After a treatment-free interval of 1 week, the
mice were kept on 0.05% PB-containing water whereas the
control group was kept on PB-free water for 19 weeks. To
examine the prophylactic activities of bicyclol, the animals
were pretreated with bicyclol (100, 200mg/kg) administered
orally 2 days before DEN injection. After DEN injection,
bicyclol was administered once daily for 6 days/week for a
period of 20 weeks.
The mice were weighed periodically and their body
weights were recorded. At week 20, 8–10 surviving mice of
e a c hg r o u pw e r es a c r i ﬁ c e da n d5m i c eo fe a c hg r o u pw e r e
kept on fresh water and feed for another 10 weeks. Serum
was obtained from the blood by centrifugation at 3000rpm
for 10min. Liver specimens were removed carefully after the
mice were sacriﬁced. Macroscopically visible liver tumors
and nodules greater than approximately 1mm in diameter
ontheliversurfacewererecorded.Therightlobeofeachliver
and the nodules were ﬁxed in paraformaldehyde solution for
histopathological and immunohistochemical examinations.
The remaining liver tissues were stored at −80◦Cf o r
performing biochemical, ELISA, and Western blot assays.
2.4. Histopathology. The ﬁxed liver samples were processed
a n de m b e d d e di np a r a ﬃn blocks. Tissue block sections were
mounted on slides, deparaﬃnized in xylene, dehydrated in
alcohol, and sections with a thickness of 5μm were prepared.
Then, the sections were stained with hematoxylin and eosin
(H&E). Liver pathological changes and the extent of liver
tumors were observed and diagnosed under a microscope by
a histopathologist.
2.5. Biochemical Assays of AST, ALT, and ALP. The serum
levelsofAST,ALT,andALPweremeasuredusingcommercial
kits (Beihuakangtai Chemical Reagent Co., Ltd, Beijing,
China).
2.6. Enzyme-Linked Immunosorbent Assay (ELISA) of AFP.
Quantitative estimation of the tumor marker AFP in liverJournal of Biomedicine and Biotechnology 3
and serum followed the corresponding protocols of the
kits (Shanghai Shenxiong Biotech Company, Shanghai,
China). Serum was obtained from blood by centrifugation
at 3000rpm for 10min. Liver tissue was homogenized in
an electron/grass homogenizer (DY89-I, Ningbo., China)
using cold normal saline at 4◦C. Then, the homogenates
werecentrifuged.Aliquotsofthesupernatantsandtheserum
were used to quantify AFP. The total proteins in liver
homogenates were determined by the Lowry methods using
bovine serum albumin as the standard. Optical density was
measured using scanning full wavelength spectrophotometer
(MQX200, BIO-TEK, USA).
2.7. Western Blot Analysis of PCNA. The liver tissue was
homogenized in an electron/grass homogenizer (Dounce,
Ningbo, China) using sodium dodecyl sulfate polyacry-
lamide gel electrophoresis (SDS-PAGE) lysis buﬀer (50mM
Tris-HCL, 150mM NaCl, 5mM EDTA, 0.3% Triton X-100,
0.03% SDS, 1μg/mL aprotinin, 1μg/mL leupeptin, 1mM
PMSF) at 4◦C. After incubation on ice for 30min, the
homogenates were centrifuged at 12000g for 20min and the
supernatants were boiled in an SDS sample loading buﬀer
for 4min before electrophoresis on SDS-polyacrylamide
gel. After electrophoresis for 2∼3h, proteins in the SDS-
PAGE gel were transferred to nitrocellulose membranes at
27mA for 12h at 4◦C. The membranes were blocked in
5% milk-Tris buﬀered saline with Tween 20 (TBST) (20mM
Tris-HCl, pH 7.5, 500 Mm NaCl, 0.1% Tween 20) at 4◦C
overnight. The blot was probed with a mouse anti-PCNA
monoclonal antibody (Santa Cruz Biotechnology Inc., USA)
at a dilution of 1:200 in 5% milk-TBST for 2h at room tem-
perature and then incubated with an alkaline-phosphatase-
conjugated secondary antibody in skim milk-TBST for 1.5h
at room temperature. The blot was developed using the 5-
bromo-4-chloro-3-indolyl phosphate-nitro blue tetrazolium
(BCIP/NBT) colorimetric method, and the densities of the
bands were determined using the Gel-Pro Analyzer 4.0
software.
2.8.Immunohistochemistry. Theparaﬃn-embeddedlivertis-
sue was cut into 5μm thick sections, deparaﬃnized, and
incubated in 3% H2O2 for 10min to quench endogenous
peroxidase activity. After blocking with normal goat serum
for 20min, the sections were stained with a mouse anti-
AFP monoclonal antibody (Sigma Chemical Co., USA)
and mouse anti-PCNA monoclonal antibody (Santa Cruz
Biotechnology Inc., USA) at 4◦C overnight, followed by
incubation with a horseradish-peroxidase-conjugated goat
anti-mouse antibody at 37◦C for 30min. The antibody bind-
ing sites were visualized by incubation with diaminobenzi-
dine (DAB)-H2O2 at room temperature for 10min. Digital
images of AFP and PCNA immunoreactive liver cells were
acquired at 100x magniﬁcation on an Olympus microscope
(Olympus, Tokyo, Japan) using an attached Polaroid digital
microscope camera (Polaroid, Cambridge, MA, USA) and
IBM PC.
2.9. Statistical Analysis. The data were presented as the mean
± SD. ANOVA was used for multiple comparisons of groups.
The statistical signiﬁcance between groups was assessed by
thepairedStudent’st-test.AvalueofP<0.05wasconsidered
to be signiﬁcant.
3. Results
The chemopreventive eﬀect of bicyclol on DEN/PB-induced
hepatocellular cancer was elucidated in male ICR mice. At
week20, DEN/PB-inducedtumorsornodulescouldberead-
ily observed by unaided eyes (Figure 2(a)). All macroscopi-
cally visible liver nodules greater than approximately 1mm
in diameter were counted. Oral administration of bicyclol
before tumor initiation resulted in a marked inhibition of
tumor development in the animals. The average number
of nodules per liver in the bicyclol-treated groups was
signiﬁcantly lower than those in the DEN/PB model group
(Figure 2(b)). In addition, the body weight of the animals
decreased on DEN/PB administration when compared to
the control group. Pretreatment with bicyclol prevented the
decrease in body weight (Figure 3).
In the histopathological examination of liver tissue
at week 20, the control group animals revealed normal
architecture. DEN/PB-induced animals showed loss of archi-
tecture and presence of tumor cells. Animals pretreated
with bicyclol (100, 200mg/kg) showed fewer neoplastic
cells, near-normal architecture, and signiﬁcant improvement
in liver histopathology (Figure 4). The tumor extent was
diagnosed and evaluated by a histopathologist. As shown in
Table 1, DEN initiation followed by PB promotion resulted
in 33.3% hepatocellular cancer, 55.6% hepatoma, and 88.9%
multiple bile canaliculi hyperplasia formations in the liver.
Preadministration of bicyclol showed a signiﬁcant reduction
in the incidence of liver tumors. Bicyclol administered at a
dose of 200mg/kg exhibited a stronger preventive eﬀect on
liver carcinogenesis as hepatocellular cancer and hepatoma
were not observed in the mice at week 20, but 50.0% low-
grade multiple bile canaliculi hyperplasia formations were
observed.
Table 2 shows the levels of serum marker enzymes: ALT,
AST, and ALP. DEN initiation and PB promotion resulted in
a marked increase in serum ALT and ALP levels as compared
to those in the control group whereas no marked changes
were observed in the serum AST levels. Pretreatment with
100mg/kg bicyclol reduced serum ALT levels signiﬁcantly.
However, bicyclol administered at a dose of 200mg/kg failed
to considerably change the abovementioned levels of ALT,
AST, and ALP.
Figure 5(b) depicts the levels of the tumor marker AFP in
serum and liver by using the ELISA assay. DEN initiation fol-
lowed by PB promotion resulted in a marked increase in AFP
levels in liver and serum as compared with that of the control
group. Pretreatment with bicyclol signiﬁcantly decreased the
AFP level. Bicyclol also reduced the serum AFP level, while
there was no statistical signiﬁcance when compared with
the model group because of the large standard deviation.
In the immunohistochemistry assay (Figure 5(a)), the AFP4 Journal of Biomedicine and Biotechnology
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Figure 2: Gross liver tumor and nodule phenotypes in DEN/PB-induced ICR mice and the preventive eﬀect of bicyclol at week 20. (a)
Photographs of representative livers. (b) Determination of liver tumor and number of nodules per liver greater than approximately 1mm in
diameter. Average values with standard deviations are shown. n = 8–10. ##P<0.01 compared with the control group; ∗P<0.01, ∗∗P<0.01
compared with the DEN/PB model group.
Table 1: The incidence of liver tumors induced by DEN/PB in mice and the eﬀect of bicyclol determined by H&E staining and histological
evaluation.
Group Dosage
(mg/kg) HCC Hepatoma Cholangioadenoma Capillary
hemangioma MBCA
Control — 0.0 (0/6) 0.0 (0/6) 0.0 (0/6) 0.0 (0/6) 0.0 (0/6)
DEN/PB — 33.3 (3/9) 55.6 (5/9) 22.2(2/9) 11.1 (1/9) 88.9 (8/9)
Bicyclol 100 11.1 (1/9) 22.2 (2/9) 11.1(1/9) 0.0 (0/9) 33.3 (3/9)
200 0.0 (0/8) 0.0 (0/8) 0.0 (0/8) 0.0 (0/8) 50.0 (4/8)
HCC: hepatocellular carcinoma; MBCA: multiple bile canaliculi hyperplasia.
immunoreactivity in Page: 9 DEN/PB-induced liver cells was
more intense than that in the control liver cells. Pretreatment
with bicyclol markedly decreased the expression of AFP.
Using the same ELISA kit, we also found that bicyclol did
not exhibit any lowering eﬀect on the physiological elevation
of serum AFP in pregnant mice and fetal mice livers treated
with bicyclol 200mg/kg for 10 days (Figure 5(c)).
Figure 6 reveals the immunohistochemical and Western
blot analysis of PCNA. In immunohistochemical analysis
(Figure 6(a)),theliversectionsofthecontrolmicestainedfor
PCNA showed few nuclear-positive cells. However, DEN/PB
treatment remarkably increased not only the intensity of
immunostainingbutalsothenumberofPCNA-positivehep-
atocytes, which were both signiﬁcantly reduced with bicyclol
pretreatment. In the Western blot assay, preadministered
bicyclol also decreased the increased expression of PCNA
induced by DEN/PB (Figure 6(b)).
In this study, we also found that 10 weeks after stopping
the administration of PB and drugs,the controland bicyclol-
treated (200mg/kg) animals showed no HCC and hepatoma
formation at the time of termination whereas DEN/PB-
induced mice developed 100% hepatoma and 50% HCC
(data not shown).
4. Discussion
DEN is a potent hepatocarcinogenic nitrosamine present in
tobaccosmoke,water,cheddarcheese,curedandfriedmeats,Journal of Biomedicine and Biotechnology 5
Table 2: Levels of serum marker enzymes ALT, AST, and ALP in all groups.
Group Dosage
(mg/kg) AST (u/L) ALT (u/L) ALP (u/L)
Control — 332.0 ±32.8 182.9 ±25.75 .3 ±1.2
DEN/PB — 334.1 ±32.1 283.5 ±55.9## 10.8 ±6.4#
Bicyclol 100 324.3 ±19.1 224.4 ±23.3∗∗ 8.4 ±4.3
200 350.5 ±45.6 222.2 ±53.87 .8 ±2.2
Data are means ± SD values (n = 8 ∼10). #P<0.05, ##P<0.01, compared with the control group. ∗∗P<0.01 compared with the DEN/PB model group.
Control Bicyclol 100 mg/kg + DEN/PB
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Figure 3: Body weight proﬁle in the control and experimental
groups. Average values with standard deviations are shown. n = 14-
15.
occupational settings, cosmetics, agricultural chemicals, and
pharmaceutical agents. DEN-induced HCC is one of the
mostacceptedandwidelyusedexperimentalmodelstostudy
hepatocarcinogenesis [11]. There are 2 liver tumorigenesis
protocols for DEN. DEN treatment at the neonatal period
(2-week-old mice administered with DEN at a dose of
5mg/kg body weight) causes severe hepatocyte toxicity.
DEN treatment of young adult mice (4-5-week-old mice
administered with DEN at a dose of 100mg/kg body weight)
is less toxic and requires tumor promotion by long-term
treatment with PB, a procedure referred to as the two-stage
protocol [12–14].
In this study, we used the DEN/PB two-stage protocol to
determine whether bicyclol has a chemopreventive eﬀect on
hepatocarcinogenesis in vivo. As female mice are known to
be resistant to hepatocarcinogenesis in experimental mouse
models, including those employing chemical carcinogenesis,
o n l ym a l em i c ew e r eu s e da n da n a l y z e di no u re x p e r i m e n t s
[15]. In this study, we found that pretreatment with bicyclol
(100, 200mg/kg orally) markedly decreased the number of
liver tumor nodules per liver. According to the histopatho-
logical diagnosis, the model control group developed 33.3%
HCC and 55.6% hepatoma at week 20. However, the mice
pretreated with 200mg/kg bicyclol showed no HCC and
hepatoma formation in their liver. Ten weeks after stopping
administration of the promoter and bicyclol, there was still
notumorformationinthe200mg/kgbicyclolgroupwhereas
100% hepatoma and 50% HCC was observed in the DEN/PB
model group. These results further revealed that bicyclol
had a preventive eﬀect on hepatocarcinogenesis induced by
carcinogens and this preventive activity is persistent.
Liver damage caused by DEN and PB could result in
the deterioration or destruction of the cell membrane which
leads to the leakage of transaminases and ALP from the
liver tissue. The serum levels of transaminases and ALP are
representative of the liver function; their increased levels
are indicators of liver damage. Cancer chemoprevention
and therapy depends on the investigation of these marker
enzymes [16]. The elevation of ALT levels is repeatedly cred-
ited to hepatocellular damage and is usually accompanied
by a rise in AST levels. Increase in ALP levels reﬂects the
pathological alteration in biliary ﬂow. In the present study,
pretreatment with bicyclol attenuated the increased activities
of ALT and ALP induced by DEN/PB, but only bicyclol-
(100mg/kg) treated mice showed statistically signiﬁcant
results when compared with the DEN/PB group. There were
no changes in serum AST levels in the model and bicyclol-
treated groups. It is shown that bicyclol helps regenerate the
parenchymal cells in liver, protecting membrane integrity
andtherebydecreasingenzymeleakage(resultsin[6]).These
results shown in this paper also suggest that the protective
eﬀect on cell membranes is not the major mechanism by
which the chemopreventive eﬀect of bicyclol is exerted.
AFP, an oncofetal serum protein, is progressively lost
during development, such that it is virtually absent from
a healthy adult [17, 18]. It has been widely used as a
clinical marker in the diagnosis and monitoring of HCC.
As we previously reported in human hepatocellular carci-
noma MHCC97-H cells with high metastatic potential [19],
bicyclol pretreatment signiﬁcantly decreased the production
and secretion of AFP. Since AFP overexpression has been
associated with uncontrolled growth of HCC [20], our data
suggests that bicyclol prevented the progression of HCC that
is associated with the downregulation of cell proliferation.
Another ﬁnding in this study is that bicyclol does not
signiﬁcantly aﬀect the physiological AFP levels in pregnant
mice and fetal mice livers. These ﬁndings indicate that the
lowering eﬀect of bicyclol on AFP is selective. This is an
interesting ﬁnding, and further studies need to be carried
out.6 Journal of Biomedicine and Biotechnology
Control DEN/PB model
Bicyclol 100 mg/kg Bicyclol 200 mg/kg
Figure 4: Histological study of the liver tissue obtained from the control and experimental groups at week 20. H&E-stained liver sections
werephotographedat100xmagniﬁcation.Insetsinthebottom-leftcornersareimagesat20xmagniﬁcationofthelivertissuefromwhichthe
100x photographs were taken. Control group animals revealed normal architecture. DEN/PB-induced animals showed loss of architecture
and presence of cancer cells. Animals pretreated with bicyclol (100, 200mg/kg) showed fewer neoplastic cells and near-normal architecture.
PCNA is another marker of cell proliferation. It plays
an essential role in nucleic acid metabolism as a compo-
nent of the replication and repair machinery [21]. This
toroidal-shaped protein encircles the DNA and can slide
bidirectionally along the duplex. PCNA has been identiﬁed
as the DNA polymerase delta accessory protein. In our
studies, the expression of PCNA signiﬁcantly increased in
DEN/PB-induced mice in terms of the number of PCNA-
positive hepatocytes examined by immunohistochemistry,
and the expression of PCNA was quantiﬁed by Western blot
assay. Pretreatment with bicyclol decreased the expression
of PCNA. This data suggests that bicyclol prevents the
development of liver tumors along with the inhibition of cell
proliferation.
In addition, cytochrome P450 (CYP) monooxygenase
also plays a critical role in the activation of various chemical
toxicants and precarcinogens [22–24]. Metabolic activation
of DEN by CYP enzymes to form reactive electrophiles is
required for its toxicity, and PB induces a large spectrum of
drug-metabolizing enzymes [25]. According to the results of
previous studies [26–28], bicyclol had the modulating activ-
ityonCYPisozymes,includingthemildinhibitiontoCYP2C
and CYP2D, the mild induction to CYP2E1, and reducing
the metabolic rates of the selective substrates of CYP3A,
1A2, 2E1, and 2C. Bicyclol could enhance particularly the
denitrosation of DEN, a low toxic pathway of metabolism.
Based on these preliminary results, the modulating activity
on CPY isozymes of bicyclol may also partly contribute to
the prevention eﬃcacy on hepatocarcinogenesis induced by
DEN and PB found in this paper.
5. Conclusions
In summary, the ﬁndings of the present in vivo study are
consistent with the results of our in vitro studies where we
found that bicyclol prevents the malignant transformation
of WB-F344 cells induced by 3MC and TPA [10]. Taken
together, bicyclol has chemopreventive potential to the liver
carcinogenesis induced by carcinogens. This is an interesting
ﬁnding, and further studies on whether bicyclol can prevent
liver carcinogenesis induced by chronic viral hepatitis need
to be carried out. Additional studies to understand other
molecular mechanisms responsible for its chemopreventive
eﬃcacy are warranted to claim bicyclol as a potential chemo-
preventive agent against liver cancer induced by carcinogens.
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Figure 5: Expression and quantiﬁcation of α-fetal protein (AFP). (a) AFP-immunoreactivity assay in the control and experimental groups
at week 20 using immunohistochemistry assay. (A) control; (B) DEN/PB model; (C) treatment with bicyclol (100mg/kg) before DEN
injection; (D) treatment with bicyclol (200mg/kg) before DEN injection. (b) Quantiﬁcation of serum and tissue AFP levels in the control
and experimental groups at week 20 using an enzyme immunoassay kit. Average values with standard deviations are shown. n = 8–10.
#P<0.05 compared with the control group; ∗P<0.05, ∗∗P<0.01 compared with the DEN/PB model group. (c) Quantiﬁcation of liver
AFP levels in pregnant mice and fetal mice using an enzyme immunoassay kit. Average values with standard deviations are shown. n = 4.
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Figure 6: Expression of PCNA in the control and experimental groups at week 20. (a) Representative microscopic pictures of PCNA-stained
liver sections by immunohistochemical analysis (100×) and quantiﬁcation of the immunostained section of PCNA. ##P<0.01 compared
withthecontrolgroup; ∗P<0.05, ∗∗P<0.01comparedwiththeDEN/PBmodelgroup.(b)WesternblotassayofPCNAandthequantitative
results obtained by measuring the optical density of each band and expressed as the ratio of each targeted protein and beta-actin. Average
values of 3 separate experiments along with the standard deviations are shown. ##P<0.01 compared with the control group; ∗P<0.05
compared with the DEN/PB model group.
HCV: Hepatitis C virus
3MC: 3-Methylcholanthrene
PB: Phenobarbital
TPA: 12-O-tetradecanoylphorbol-13-acetate.
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